vs
Side-by-side financial comparison of Affinity Bancshares, Inc. (AFBI) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $8.6M, roughly 1.6× Affinity Bancshares, Inc.). Affinity Bancshares, Inc. runs the higher net margin — 24.9% vs -34.7%, a 59.6% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 12.8%). Over the past eight quarters, Affinity Bancshares, Inc.'s revenue compounded faster (8.1% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
AFBI vs FENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $13.8M |
| Net Profit | $2.1M | $-4.8M |
| Gross Margin | — | — |
| Operating Margin | 35.9% | -18.5% |
| Net Margin | 24.9% | -34.7% |
| Revenue YoY | 12.8% | 73.8% |
| Net Profit YoY | 58.5% | -141.1% |
| EPS (diluted) | $0.34 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | $13.8M | ||
| Q3 25 | $8.4M | $12.5M | ||
| Q2 25 | $8.3M | $9.7M | ||
| Q1 25 | $7.8M | $8.8M | ||
| Q4 24 | $7.6M | $7.9M | ||
| Q3 24 | $8.0M | $7.0M | ||
| Q2 24 | $8.3M | $7.3M | ||
| Q1 24 | $7.3M | $25.4M |
| Q4 25 | $2.1M | $-4.8M | ||
| Q3 25 | $2.2M | $-638.0K | ||
| Q2 25 | $2.2M | $-3.2M | ||
| Q1 25 | $1.8M | $-1.2M | ||
| Q4 24 | $1.3M | $-2.0M | ||
| Q3 24 | $1.7M | $-5.7M | ||
| Q2 24 | $1.0M | $-5.6M | ||
| Q1 24 | $1.3M | $12.8M |
| Q4 25 | 35.9% | -18.5% | ||
| Q3 25 | 34.9% | -1.5% | ||
| Q2 25 | 34.1% | -28.3% | ||
| Q1 25 | 30.8% | -9.2% | ||
| Q4 24 | 21.1% | -11.8% | ||
| Q3 24 | 28.5% | -74.6% | ||
| Q2 24 | 16.2% | -69.4% | ||
| Q1 24 | 24.0% | 54.2% |
| Q4 25 | 24.9% | -34.7% | ||
| Q3 25 | 26.5% | -5.1% | ||
| Q2 25 | 25.9% | -32.7% | ||
| Q1 25 | 23.4% | -13.3% | ||
| Q4 24 | 17.7% | -25.0% | ||
| Q3 24 | 21.7% | -82.2% | ||
| Q2 24 | 12.5% | -76.5% | ||
| Q1 24 | 18.2% | 50.6% |
| Q4 25 | $0.34 | $-0.17 | ||
| Q3 25 | $0.34 | $-0.02 | ||
| Q2 25 | $0.33 | $-0.11 | ||
| Q1 25 | $0.28 | $-0.04 | ||
| Q4 24 | $0.21 | $-0.02 | ||
| Q3 24 | $0.26 | $-0.21 | ||
| Q2 24 | $0.16 | $-0.20 | ||
| Q1 24 | $0.20 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.9M | $36.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $127.0M | $35.5M |
| Total Assets | $881.7M | $70.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.9M | $36.8M | ||
| Q3 25 | $84.8M | $21.9M | ||
| Q2 25 | $89.7M | $18.7M | ||
| Q1 25 | $74.7M | $22.7M | ||
| Q4 24 | $41.4M | $26.6M | ||
| Q3 24 | $52.3M | $40.3M | ||
| Q2 24 | $50.4M | $43.1M | ||
| Q1 24 | $61.4M | $51.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | $19.4M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $19.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | $32.1M | ||
| Q2 24 | — | $31.8M | ||
| Q1 24 | — | $31.3M |
| Q4 25 | $127.0M | $35.5M | ||
| Q3 25 | $125.4M | $-4.5M | ||
| Q2 25 | $124.1M | $-7.5M | ||
| Q1 25 | $122.3M | $-5.9M | ||
| Q4 24 | $129.1M | $-5.9M | ||
| Q3 24 | $128.4M | $-5.2M | ||
| Q2 24 | $125.1M | $-1.4M | ||
| Q1 24 | $123.3M | $3.0M |
| Q4 25 | $881.7M | $70.6M | ||
| Q3 25 | $925.2M | $49.3M | ||
| Q2 25 | $933.8M | $44.9M | ||
| Q1 25 | $912.5M | $46.4M | ||
| Q4 24 | $866.8M | $44.9M | ||
| Q3 24 | $878.6M | $58.9M | ||
| Q2 24 | $873.6M | $63.2M | ||
| Q1 24 | $869.5M | $69.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.6M | $-6.0M |
| Free Cash FlowOCF − Capex | $11.2M | — |
| FCF MarginFCF / Revenue | 130.9% | — |
| Capex IntensityCapex / Revenue | 4.9% | — |
| Cash ConversionOCF / Net Profit | 5.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $20.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $-6.0M | ||
| Q3 25 | $3.7M | $1.5M | ||
| Q2 25 | $3.8M | $-3.7M | ||
| Q1 25 | $1.9M | $-4.3M | ||
| Q4 24 | $6.8M | $-1.5M | ||
| Q3 24 | $4.1M | $-2.2M | ||
| Q2 24 | $619.0K | $-8.4M | ||
| Q1 24 | $1.2M | $39.0M |
| Q4 25 | $11.2M | — | ||
| Q3 25 | $3.6M | — | ||
| Q2 25 | $3.7M | — | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | $6.4M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $489.0K | — | ||
| Q1 24 | $1.1M | — |
| Q4 25 | 130.9% | — | ||
| Q3 25 | 43.3% | — | ||
| Q2 25 | 44.0% | — | ||
| Q1 25 | 22.7% | — | ||
| Q4 24 | 83.9% | — | ||
| Q3 24 | 49.5% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 14.8% | — |
| Q4 25 | 4.9% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 5.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.6% | — | ||
| Q1 24 | 1.8% | — |
| Q4 25 | 5.46× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
